AI-based rare disease diagnostic company 3billion (CEO Changwon Geum) announced on the 11th that it recorded annual sales of KRW 11.7 billion, a 103% increase year-on-year, through its provisional performance disclosure based on consolidated figures for 2025.
This sales figure exceeded the 2025 target of KRW 9 billion set at the time of listing by approximately 30%, and also surpassed the recent market forecast of KRW 10.8 billion. Last year's fourth quarter sales reached KRW 3.9 billion, marking the company's highest quarterly performance ever.
Improvements were also evident in the profit structure. Operating loss in 2025 decreased by approximately 20% to KRW 5.9 billion, compared to KRW 7.4 billion the previous year. The operating loss-to-sales ratio improved by 78 percentage points, from 128% in 2024 to 50% in 2025. The company explained that operating efficiency was enhanced as sales growth led to improved profitability through continued global sales expansion and R&D investments.
3billion has maintained a three-year sales growth trend, more than doubling its annual revenue, for three consecutive years since 2023. This growth is attributed to the growing demand for whole-exome (WES) and whole-genome (WGS)-based diagnostic testing in the global market. The company maintained a 67.4% share of its overseas sales, leveraging its global network of approximately 80 countries, and has also expanded its partnerships with major domestic hospitals and pharmaceutical companies.
Geum Chang-won, CEO of 3billion, said, “2025 is the year in which we will demonstrate our AI-based diagnostic technology in the global market,” and added, “With the establishment of our Austin laboratory in the U.S. as an opportunity, we plan to target the North American market and expand our testing scale.”
- See more related articles
You must be logged in to post a comment.